Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy

The previously reported efficacy and safety of HER3-DXd in heavily pretreated patients with <i>EGFR</i>-mutated NSCLC are also observed in those with other NSCLC subtypes and warrant further clinical evaluation.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-06-24
DOI
https://doi.org/10.1200/jco-24-02744
Citations
8
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
12.15
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy

Egbert F. Smit, Xin Su, David Sternberg, Haruyasu Murakami et al.
8 citations
Journal of Clinical Oncology
Lung Cancer Treatments and Mutations
12.15
article

Patritumab Deruxtecan (HER3-DXd; MK-1022) in Non–Small Cell Lung Cancer After Platinum-Based Chemotherapy and Immunotherapy

Egbert F. Smit, Xin Su, David Sternberg, Haruyasu Murakami, Erminia Massarelli, Wu‐Chou Su, Hidetoshi Hayashi, Kathryn A. Gold, Sang‐We Kim, Pang‐Dian Fan, Pasi Antero Janne, Melissa L. Johnson, Christina S. Baik, K Landry Truchon, Masahiro Fujimura, Makoto Nishio, Conor Steuer, Enriqueta Felip, Dong‐Wan Kim
article en
8 citations

Abstract

The previously reported efficacy and safety of HER3-DXd in heavily pretreated patients with <i>EGFR</i>-mutated NSCLC are also observed in those with other NSCLC subtypes and warrant further clinical evaluation.

Journal of Clinical OncologyVol. 43(25)
Ulsan College (KR), Seattle Cancer Care Alliance (US), Emory University (US), University of Washington (US), UC San Diego Health System (US), Asan Medical Center (KR), Seoul National University Hospital (KR), The Netherlands Cancer Institute (NL), University of Ulsan (KR), Shizuoka Cancer Center (JP), Sarah Cannon (US), City of Hope (US), Dana-Farber Cancer Institute (US), Vall d'Hebron Hospital Universitari (ES), Tennessee Oncology (US), The Cancer Institute Hospital (JP), National Cheng Kung University Hospital (TW), Daiichi Sankyo (United States) (US), Vall d'Hebron Institute of Oncology (ES), Kindai University (JP)
Good health and well-being
Openalex Percentile: Top 1%
Lung Cancer Treatments and Mutations
12.15
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.